Home LiteratureArticle Details
PMID: 9971778 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.

Journal of virology ·Vol. 73 ·No. 3 ·1999-03-00 ·Pages 1980-9

Ruf IK, Moghaddam A, Wang F, Sample J

Abstract

Epstein-Barr virus (EBV), the only known human lymphocryptovirus (LCV), displays a remarkable degree of genetic and biologic identity to LCVs that infect Old World primates. Within their natural hosts, infection by these viruses recapitulates many key aspects of EBV infection, including the establishment of long-term latency within B lymphocytes, and is therefore a potentially valuable animal model of EBV infection. However, it is unclear whether these LCVs have adopted or maintained the same mechanisms used by EBV to express essential viral proteins, such as EBNA-1, in the face of cell-mediated repression of EBV gene expression that occurs upon establishment of the asymptomatic carrier state. To address this issue, we determined whether the endogenous LCVs of baboon (Cercopithecine herpesvirus 12) and rhesus macaque (Cercopithecine herpesvirus 15) have the functional equivalent of the EBV promoter Qp, which mediates exclusive expression of EBNA-1 during the restricted programs of EBV latency associated with the carrier state. Our results indicate that (i) both the baboon and rhesus macaque LCVs have a genomic locus that is highly homologous to the EBV Qp region, (ii) key cis-regulatory elements of Qp are conserved in these LCV genomes and compose promoters that are functionally indistinguishable from EBV Qp, and (iii) EBNA-1 transcripts identical in structure to EBV Qp-specific EBNA-1 mRNAs are present in nonhuman LCV-infected cells, demonstrating that these Qp homologs are indeed utilized as alternative EBNA-1 promoters. These observations indicate that the molecular mechanisms which regulate EBV gene expression during restricted latency have been conserved among the LCVs. The contribution of these mechanisms to viral persistence in vivo can now be experimentally tested in nonhuman primate models of LCV infection.

MeSH Terms
Animals B-Lymphocytes/virology Base Sequence Cells, Cultured DNA, Viral/chemistry Epstein-Barr Virus Nuclear Antigens/genetics Homeostasis Lymphocryptovirus/genetics Molecular Sequence Data Papio Promoter Regions, Genetic TATA Box Transcription, Genetic Virus Latency
Chemicals
DNA, Viral Epstein-Barr Virus Nuclear Antigens
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ruf I K
Program in Viral Oncogenesis and Tumor Immunology, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Moghaddam A
Wang F
Sample J
References (73)
73 references, click to expand
  1. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood.
    Blood. 1999 May 1;93(9):3026-32 PMID: 10216099
  2. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
    J Virol. 1992 May;66(5):2689-97 PMID: 1313894
  3. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.
    J Virol. 1992 Jun;66(6):3715-24 PMID: 1316478
  4. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    J Exp Med. 1992 Jul 1;176(1):157-68 PMID: 1319456
  5. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
    J Virol. 1992 Aug;66(8):4654-61 PMID: 1321268
  6. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.
    J Virol. 1992 Nov;66(11):6461-9 PMID: 1328675
  7. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    J Virol. 1992 Dec;66(12):7461-8 PMID: 1331531
  8. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    J Exp Med. 1992 Jul 1;176(1):169-76 PMID: 1377222
  9. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.
    Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6343-7 PMID: 1648738
  10. Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.
    Nucleic Acids Res. 1991 May 11;19(9):2435-40 PMID: 1710355
  11. Epstein-Barr virus and nonhuman primates: natural and experimental infection.
    Adv Cancer Res. 1976;23:171-201 PMID: 179290
  12. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro.
    Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1546-50 PMID: 1847527
  13. Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease.
    Intervirology. 1977;8(4):240-9 PMID: 194867
  14. Transformation of lymphocytes by Herpesvirus papio.
    Int J Cancer. 1977 Aug 15;20(2):219-26 PMID: 197025
  15. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes.
    Proc Natl Acad Sci U S A. 1990 Mar;87(5):1725-9 PMID: 2155423
  16. Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes.
    J Virol. 1990 Apr;64(4):1667-74 PMID: 2157049
  17. Plasmid origin of replication of herpesvirus papio: DNA sequence and enhancer function.
    J Virol. 1990 Jun;64(6):2876-83 PMID: 2159548
  18. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    J Gen Virol. 1990 Jul;71 ( Pt 7):1481-95 PMID: 2165133
  19. Oncogenic herpesviruses of nonhuman primates.
    Comp Immunol Microbiol Infect Dis. 1979;2(2-3):229-41 PMID: 228897
  20. EBV gene expression in an NPC-related tumour.
    EMBO J. 1989 Sep;8(9):2639-51 PMID: 2479554
  21. Adeno-associated virus rep protein synthesis during productive infection.
    J Virol. 1989 Feb;63(2):873-82 PMID: 2536109
  22. A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus.
    J Virol. 1987 Nov;61(11):3424-30 PMID: 2822952
  23. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
    J Gen Virol. 1988 May;69 ( Pt 5):1051-65 PMID: 2836550
  24. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
    Int J Cancer. 1988 Sep 15;42(3):329-38 PMID: 2843473
  25. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
    Nature. 1985 Oct 17-23;317(6038):629-31 PMID: 2997615
  26. Epstein-Barr virus-related herpesvirus from a rhesus monkey (Macaca mulatta) with malignant lymphoma.
    Int J Cancer. 1986 Sep 15;38(3):425-32 PMID: 3017870
  27. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells.
    EMBO J. 1986 Oct;5(10):2599-607 PMID: 3023050
  28. Human growth hormone as a reporter gene in regulation studies employing transient gene expression.
    Mol Cell Biol. 1986 Sep;6(9):3173-9 PMID: 3023965
  29. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site.
    Proc Natl Acad Sci U S A. 1986 Jul;83(14):5096-100 PMID: 3460083
  30. Biologic and antigenic characteristics of Epstein-Barr virus-related Herpesviruses of chimpanzees and baboons.
    Int J Cancer. 1977 Sep 15;20(3):448-59 PMID: 409690
  31. EBV antibody in sera of non-human primates.
    Nature. 1972 Aug 11;238(5363):353-4 PMID: 4342526
  32. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.
    Proc Natl Acad Sci U S A. 1973 Sep;70(9):2487-91 PMID: 4354852
  33. DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
    Nature. 1984 Jul 19-25;310(5974):207-11 PMID: 6087149
  34. Infection of rhesus monkeys and chimpanzees with Epstein-Barr virus.
    Arch Virol. 1980;66(4):341-51 PMID: 6255902
  35. Herpesvirus papio DNA is similar in organization to Epstein-Barr virus DNA.
    J Virol. 1981 Feb;37(2):698-709 PMID: 6261014
  36. Colinearity between the DNAs of Epstein-Barr virus and herpesvirus papio.
    J Virol. 1981 Feb;37(2):821-6 PMID: 6261021
  37. Comparative studies of herpesvirus papio (baboon herpesvirus) DNA and Epstein-Barr virus DNA.
    J Gen Virol. 1980 Dec;51(Pt 2):245-53 PMID: 6262436
  38. Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells.
    J Virol. 1982 Feb;41(2):376-89 PMID: 6281455
  39. DNA of herpesvirus pan, a third member of the Epstein-Barr virus-Herpesvirus papio group.
    J Virol. 1982 Mar;41(3):931-9 PMID: 6284982
  40. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.
    Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10565-9 PMID: 7479841
  41. 5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio.
    J Virol. 1995 Dec;69(12):8011-9 PMID: 7494314
  42. A novel form of Epstein-Barr virus latency in normal B cells in vivo.
    Cell. 1995 Feb 24;80(4):593-601 PMID: 7532548
  43. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines.
    J Virol. 1995 Aug;69(8):5039-47 PMID: 7609074
  44. Host factors LR1 and Sp1 regulate the Fp promoter of Epstein-Barr virus.
    Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8293-7 PMID: 7667284
  45. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.
    J Virol. 1995 Jun;69(6):3752-8 PMID: 7745723
  46. Characterization of the Epstein-Barr virus Fp promoter.
    Virology. 1995 Jan 10;206(1):183-95 PMID: 7831773
  47. Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk.
    J Virol. 1995 Mar;69(3):1944-50 PMID: 7853539
  48. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
    J Virol. 1994 Nov;68(11):7374-85 PMID: 7933121
  49. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.
    Mol Cell Biol. 1994 Nov;14(11):7144-52 PMID: 7935429
  50. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA.
    J Virol. 1995 Jan;69(1):231-8 PMID: 7983714
  51. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1.
    Cell. 1994 Jun 17;77(6):829-39 PMID: 8004672
  52. Epstein-Barr virus: adaptation to a life within the immune system.
    Trends Microbiol. 1994 Apr;2(4):125-30 PMID: 8012755
  53. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
    J Virol. 1994 Mar;68(3):1449-58 PMID: 8107208
  54. Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture.
    J Virol. 1993 Dec;67(12):7634-40 PMID: 8230482
  55. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro.
    J Virol. 1993 Apr;67(4):2006-13 PMID: 8383224
  56. EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.
    J Virol. 1993 Jun;67(6):2990-3003 PMID: 8388484
  57. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency.
    J Virol. 1993 Jun;67(6):3182-90 PMID: 8388496
  58. The lytic origin of herpesvirus papio is highly homologous to Epstein-Barr virus ori-Lyt: evolutionary conservation of transcriptional activation and replication signals.
    J Virol. 1993 Jul;67(7):4006-16 PMID: 8389916
  59. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.
    J Virol. 1996 Jan;70(1):623-7 PMID: 8523583
  60. Epstein-Barr virus and the B cell: that's all it takes.
    Trends Microbiol. 1996 May;4(5):204-8 PMID: 8727601
  61. Comparison of the EBNA1 proteins of Epstein-Barr virus and herpesvirus papio in sequence and function.
    Virology. 1996 Aug 1;222(1):1-13 PMID: 8806482
  62. Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1.
    J Virol. 1996 Nov;70(11):7819-26 PMID: 8892903
  63. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.
    Mol Cell Biol. 1997 Jan;17(1):364-77 PMID: 8972217
  64. The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element.
    J Virol. 1997 Jan;71(1):354-61 PMID: 8985357
  65. Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.
    Mol Cell Biol. 1997 Feb;17(2):873-86 PMID: 9001242
  66. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus.
    J Virol. 1997 Apr;71(4):2765-71 PMID: 9060630
  67. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes.
    Biochim Biophys Acta. 1997 Mar 20;1351(1-2):73-88 PMID: 9116046
  68. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell.
    J Virol. 1997 Jul;71(7):4882-91 PMID: 9188550
  69. An animal model for acute and persistent Epstein-Barr virus infection.
    Science. 1997 Jun 27;276(5321):2030-3 PMID: 9197263
  70. Interferon-independent and -induced regulation of Epstein-Barr virus EBNA-1 gene transcription in Burkitt lymphoma.
    J Virol. 1997 Sep;71(9):6887-97 PMID: 9261415
  71. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency.
    Mol Cell Biol. 1997 Oct;17(10):5748-57 PMID: 9315633
  72. Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus.
    J Virol. 1998 Apr;72(4):3205-12 PMID: 9525646
  73. Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).
    J Virol. 1999 Jan;73(1):826-33 PMID: 9847397
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1999-03-00
Pages
1980-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC104440
Subset
IM
Grants
NCI NIH HHS · CA65319 · United States
NCI NIH HHS · CA56639 · United States
NCI NIH HHS · R01 CA056639 · United States
NCI NIH HHS · R01 CA068051 · United States
NIAID NIH HHS · T32 AI007372 · United States
NCI NIH HHS · CA73544 · United States
NCI NIH HHS · P30 CA021765 · United States
NCI NIH HHS · R01 CA073544 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com